Search results for "SYNDROME CORONAVIRUS"

showing 10 items of 552 documents

Long‐term neuropsychiatric outcomes in COVID‐19 survivors: A 1‐year longitudinal study

2021

Longitudinal studymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)long‐COVIDCOVID-19CognitionTerm (time)cognitiveQuality of life (healthcare)psychiatricquality of lifeCOVID‐19Internal MedicineResearch LetterMedicineHumansLongitudinal StudiesSurvivorsbusinessPsychiatryJournal of Internal Medicine
researchProduct

Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

2020

AbstractThere are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor. There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm. They also act on the same mechanisms (mTOR: Mammalian target of …

MAPK/ERK pathwayARIA groupAllergy[SDV]Life Sciences [q-bio]NF-KAPPA-BdebelostReviewPharmacologyResveratrolPROTECTSchemistry.chemical_compound0302 clinical medicineRESPIRATORY SYNDROME CORONAVIRUSENDOPLASMIC-RETICULUM STRESSMedicine and Health SciencesImmunology and AllergyMedicineOXIDATIVE STRESSCOVID-19; Foods; Insulin resistance; Nrf2; Nutrients; Obesity; TRPA12. Zero hunger0303 health sciencesRESPIRATORYINSULIN-RESISTANCEMuscle cell proliferationSULFORAPHANE3. Good health[SDV] Life Sciences [q-bio]Foods030220 oncology & carcinogenesisSIGNALING PATHWAYSignal transductionLife Sciences & BiomedicinePulmonary and Respiratory MedicineNRF2 ACTIVATORSMUSCLE-CELL PROLIFERATIONImmunology610 Medicine & healthLung injurySettore MED/10 - Malattie Dell'Apparato RespiratorioTRPA1Nrf2ACUTE LUNG INJURY03 medical and health sciencesInsulin resistanceCOVID-19 Foods Insulin resistance Nrf2 Nutrients Obesity TRPA1udc:616.9odpornost proti inzulinuSULFORAPHANE PROTECTSObesityTranscription factorPI3K/AKT/mTOR pathway030304 developmental biologyScience & Technologybusiness.industrySARS-CoV-2foodCOVID-19Insulin resistanceNutrientsmedicine.diseasechemistryhranilaSYNDROME CORONAVIRUSbusinesshranaGREEN TEA
researchProduct

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG

2020

Introduction: The 2019 Coronavirus disease (COVID-19) has been characterized as a pandemic, representing a serious global public health emergency. Serological tests have been proposed as reliable tools for detecting Coronavirus SARS-CoV-2 antibodies in infected patients, especially for surveillance or epidemiological purposes. The aim of this study is to evaluate the agreement between the IgM/IgG rapid assays, based on lateral flow immunochromatographic assay, and the fully automated 2019-nCoV IgM and IgG, based on chemiluminescence immunoassay. Materials and methods: SARS-CoV-2 antibodies were measured with the BIOSYNEX COVID-19 BSS IgM/IgG test (BIOSYNEX, Illkirch-Graffenstaden, France) a…

Male030213 general clinical medicineClinical BiochemistryAntibodies Viralmedicine.disease_causeLikelihood ratios in diagnostic testinglaw.inventionSerologyCOVID-19 Testing0302 clinical medicinelawantibodiesMedicineCoronavirusImmunoassay0303 health sciencesbiologymedicine.diagnostic_testMiddle AgedantibodiePopulation SurveillanceFemaleAntibodyCLIACoronavirus InfectionsShort CommunicationConcordanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralBetacoronavirus03 medical and health sciencesimmunochromatographyHumansPandemicsAged030304 developmental biologyChemiluminescenceClinical Laboratory TechniquesSARS-CoV-2business.industryCOVID-19; serological test; antibodies; CLIA; immunochromatographyBiochemistry (medical)Reproducibility of ResultsCOVID-19serological testImmunoglobulin MImmunoglobulin GImmunoassayLuminescent MeasurementsImmunologybiology.proteinbusiness
researchProduct

Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China.

2020

Abstract Coronavirus disease 2019 (COVID‐19), an infectious outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2),1 has now progressed to global pandemic.2 Besides the compelling need to understand the novel biological pathways underlying the virulence and pathogenicity of SARS‐CoV‐2 in humans to enable the development of appropriate interventions and therapies,3,4 the noticeable difference in mortality rates between Asian and European populations is one of the most significant issues demanding the attention of biologists, epidemiologists and clinicians around the world. This article is protected by copyright. All rights reserved.

Male2019-20 coronavirus outbreakChinaCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia Viralcoronavirusmedicine.disease_causeepidemicsCOVID-19; comorbidity; coronavirus; epidemics; mortality; outbreakCOVID‐19VirologyMedicineHumansChinaPandemicsLetter to the EditorCoronavirusDemographyoutbreakbusiness.industrySARS-CoV-2OutbreakCOVID-19Middle Agedmedicine.diseaseVirologyComorbiditymortalitycomorbidityInfectious DiseasesItalyFemalebusinessJournal of medical virology
researchProduct

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

2021

Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients …

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Critical CareSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralMEDLINElcsh:MedicineLymphocyte ActivationSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingmedicineHumansAgedAged 80 and overInnate immune systembusiness.industrySARS-CoV-2lcsh:RCorrectionCOVID-19General MedicineMiddle Agedmedicine.diseasePrognosisRespiration ArtificialImmunity InnatePneumoniaImmunologyFemaleFrancebusinessJournal of Translational Medicine
researchProduct

Treatment of COVID-19 with MSCs: how does it work?

2021

The infusion of coronavirus disease 2019 (COVID-19) patients with mesenchymal stem cells (MSCs) potentially improves clinical symptoms, but the underlying mechanism remains unclear. We conducted a randomized, single-blind, placebo-controlled (29 patients/group) phase II clinical trial to validate previous findings and explore the potential mechanisms. Patients treated with umbilical cord-derived MSCs exhibited a shorter hospital stay (P = 0.0198) and less time required for symptoms remission (P = 0.0194) than those who received placebo. Based on chest images, both severe and critical patients treated with MSCs showed improvement by day 7 (P = 0.0099) and day 21 (P = 0.0084). MSC-treated pat…

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)T-LymphocytesB-Lymphocyte SubsetsAntibodies ViralMesenchymal Stem Cell TransplantationExtracellular TrapsGeneral Biochemistry Genetics and Molecular BiologyArticleImmunomodulationMiceMedicineAnimalsHumansGeneral Environmental ScienceAgedVenous Thrombosisbusiness.industrySARS-CoV-2Mesenchymal stem cellCOVID-19Middle AgedVirologyResearch HighlightMice Inbred C57BLCytoskeletal ProteinsDisease Models AnimalMechanisms of diseaseC-Reactive ProteinWork (electrical)Leukocytes MononuclearMesenchymal stem cellsCytokinesFemaleGeneral Agricultural and Biological SciencesbusinessScience China. Life Sciences
researchProduct

Hospitalizations for Stroke in France During the COVID-19 Pandemic Before, During, and After the National Lockdown.

2021

Background and Purpose: In France, the entire population was put under a total lockdown from March 17 to May 11, 2020 during the peak of the coronavirus disease 2019 (COVID-19) pandemic. Whether the lockdown had consequences on the management of medical emergencies such as stroke and transient ischemic attack (TIA) has yet to be fully evaluated. This article describes hospitalization rates for acute stroke in 2 French regions that experienced contrasting rates of COVID-19 infection, before, during, and after the nationwide lockdown (January to June 2020). Methods: All patients admitted for acute stroke/TIA into all public and private hospitals of the 2 study regions were included. Data wer…

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)EpidemiologyPandemicmedicineHumanscardiovascular diseasesStrokePandemicsAgedRetrospective StudiesAdvanced and Specialized NursingAged 80 and overEntire populationbusiness.industryIncidence (epidemiology)COVID-19Middle Agedmedicine.diseaseHospitalizationStrokeCommunicable Disease ControlFemaleNeurology (clinical)FranceCardiology and Cardiovascular MedicinebusinessDemographyStroke
researchProduct

Assessing the potential association between SARS-CoV-2 RNA load in the respiratory tract and COVID-19 mortality.

2020

Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐XI

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory System03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumans030212 general & internal medicineAgedbusiness.industrySARS-CoV-2RNACOVID-19Middle AgedViral LoadVirologyInfectious Diseasesmedicine.anatomical_structureHospital admissionRNA Viral030211 gastroenterology & hepatologyFemalebusinessBiomarkersRespiratory tractJournal of medical virology
researchProduct

1.5 vs 3 Tesla Magnetic Resonance Imaging

2021

ABSTRACT: The second part of this review deals with experiences in neuroradiological and pediatric examinations using modern magnetic resonance imaging systems with 1.5 T and 3 T, with special attention paid to experiences in pediatric cardiac imaging. In addition, whole-body examinations, which are widely used for diagnostic purposes in systemic diseases, are compared with respect to the image quality obtained in different body parts at both field strengths. A systematic overview of the technical differences at 1.5 T and 3 T has been presented in part 1 of this review, as well as several organ-based magnetic resonance imaging applications including musculoskeletal imaging, abdominal imagin…

Male3 Tesla Magnetic Resonance ImagingMusculoskeletal imaging2019-20 coronavirus outbreakmedicine.medical_specialtyMagnetic Resonance Spectroscopymedicine.diagnostic_testCoronavirus disease 2019 (COVID-19)business.industryImage qualitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Magnetic resonance imagingGeneral MedicineMagnetic Resonance ImagingmedicineHumansWhole Body ImagingRadiology Nuclear Medicine and imagingMedical physicsChildbusinessCardiac imagingInvestigative Radiology
researchProduct